Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/kyowa-kirin-co-ltd" target="_blank" data-smartkarma-citation="entities:18055:1" rel="noopener">Kyowa Kirin Co Ltd (4151 JP)</a> posted 13% revenue growth in 1Q26. Core operating margin expands 620bps to 16.9% on lower SG&amp;A and R&amp;D expense.</li>
<li>Company partially revised 2026 guidance. Core operating profit is expected to be ¥130B (vs previous ¥100B). Company now expects a higher core profit of ¥103B (vs previous ¥80B).</li>
<li>Kyowa Kirin needs new drugs to augment growth. It remains highly dependant on Crysvita. Ziftomenib, infigratinib will drive revenue numbers in medium to long term.</li>
</ul>



Kyowa Kirin Co Ltd (4151 JP) posted 13% revenue growth in 1Q26. Core operating margin expands 620bps to 16.9% on lower SG&amp;A and R&amp;D expense.
Company partially revised 2026 guidance. Core operating profit is expected to be ¥130B (vs previous ¥100B). Company now expects a higher core profit of ¥103B (vs previous ¥80B).
Kyowa Kirin needs new drugs to augment growth. It remains highly dependant on Crysvita. Ziftomenib, infigratinib will drive revenue numbers in medium to long term.


Kyowa Kirin (4151 JP): 1Q26 Revenue Grow on EMEA & Out-Licensing, Guidance Partially Revised

Doing bespoke work since 2002....., Custom Products Group

Patrick Hansen

Doing bespoke work since 2002.....

Custom Products Group

Custom Products was started 14 years ago at Lehman Brothers by current co-founder Patrick Hansen, CFA. After 3 years at Lehman, Patrick moved the team to Macquarie Securities where Simon Rigney (co-founder) joined. 3 years ago we took Custom Products independent. 

Our core strength can be summed up three words. 1- Customization - we have very little off the shelf products and most work is done on a one on one bespoke basis. 2- Speed - We pride ourselves in our ability to get requests back to the client very quickly. 3- Confidentiality - We do not redistribute. There is no grace period where we wait a week and then mass blast. Any request stops with that client.

Thematic (Sector/Industry)

It has been a while since we updated the "Hated by the Street" screen. So we thought it would be good to see which names made the list. Usually we only screen for names where the % of BUY recommendations to Total is less than 20%. However, 126 names made that list. We therefore further limited the screen by adding % of SELL recommendations greater than 30% of total recommendations. 26 names met both criteria. At the top of the list is <a href="https://www.smartkarma.com/entities/391" target="_blank" data-smartkarma-citation="entities:391:1">Sharp Corp (6753 JP)</a> with 0 BUY recommendations and 8 SELL…

It has been a while since we updated the "Hated by the Street" screen. So we thought it would be good to see which names made the list. Usually we only screen for names where the % of BUY recommendations to Total is less than 20%. However, 126 names made that list. We therefore further limited the screen by adding % of SELL recommendations greater than 30% of total recommendations. 26 names met both criteria. At the top of the list is Sharp Corp (6753 JP) with 0 BUY recommendations and 8 SELL…

Names that Are Hated and Loved by the Street in Japan....

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half. Names that could potentially beat full-year estimates. We basically screened for names that have already achieved greater than 60% of full-year consensus OP estimates and have also increased full-year Company OP guidance in the last month. <h2>Screen Criteria</h2><ol>
<li>Mkt-cap above ¥50bn</li>
<li>Fiscal year ending on March 31</li>
<li>Greater than 60% of full-year OP consensus is…</li>
</ol>

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half. Names that could potentially beat full-year estimates. We basically screened for names that have already achieved greater than 60% of full-year consensus OP estimates and have also increased full-year Company OP guidance in the last month. Screen Criteria
Mkt-cap above ¥50bn
Fiscal year ending on March 31
Greater than 60% of full-year OP consensus is…


Names Potentially Well Positioned to Beat Year-End Estimates

As I have mentioned before, a long time ago I worked at Panasonic in their IR department. One day when I was bored, I went to the Accounting department to see what was in Other Assets. One of the girls gave me an itemized list and at the bottom of that list was another Other category. Yes, in Other Assets is Other Assets.I asked to see what was in Other in Other Assets as it was 90% of the total. She just laughed and said that the Other in Other Assets was so confusing that there is no way to…

As I have mentioned before, a long time ago I worked at Panasonic in their IR department. One day when I was bored, I went to the Accounting department to see what was in Other Assets. One of the girls gave me an itemized list and at the bottom of that list was another Other category. Yes, in Other Assets is Other Assets.I asked to see what was in Other in Other Assets as it was 90% of the total. She just laughed and said that the Other in Other Assets was so confusing that there is no way to…

Names with Too Much "Other" On the Balance Sheet....

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in margin trading positions of JPX stocks as of Apr 24th. The aggregated net margin trading position is USD24,585m.</li>
<li>We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.</li>
<li>We highlight net margin buy/sell changes in Kioxia, SoftBank, Lasertec, Nintendo, Disco, Sumitomo Pharma, Fast Retailing, Furukawa Electric, Mitsubishi Heavy Industries, Toyota Motor.</li>
</ul>


We analyzed the changes in margin trading positions of JPX stocks as of Apr 24th. The aggregated net margin trading position is USD24,585m.
We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.
We highlight net margin buy/sell changes in Kioxia, SoftBank, Lasertec, Nintendo, Disco, Sumitomo Pharma, Fast Retailing, Furukawa Electric, Mitsubishi Heavy Industries, Toyota Motor.


JPX Margin Trading Weekly (Apr 24th): Kioxia, SoftBank, Lasertec, Nintendo, Disco, Sumitomo Pharma

Japan

Sumitomo Dainippon Pharma Co., Ltd. mainly manufactures and markets pharmaceuticals for human and veterinary use. The Company also produces and sells livestock feeds, food additives, and chemical products, as well as conducts clinical pathology tests for animals. Sumitomo Dainippon Pharma conducts businesses across worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sumitomo Pharma (4506 JP)

Kyowa Kirin (4151 JP): 1Q26 Revenue Grow on EMEA & Out-Licensing, Guidance Partially Revised

Kyowa Kirin sees strong revenue growth in 1Q26, with improved margins and revised profit guidance for 2026. Company looks to new drugs for future...

Tina Banerjee

Names that Are Hated and Loved by the Street in Japan....

It has been a while since we updated the "Hated by the Street" screen. So we thought it would be good to see which names made the list. Usually we...

Custom Products Group

Names Potentially Well Positioned to Beat Year-End Estimates

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half....

Custom Products Group

Names with Too Much "Other" On the Balance Sheet....

As I have mentioned before, a long time ago I worked at Panasonic in their IR department. One day when I was bored, I went to the Accounting...

Custom Products Group

JPX Margin Trading Weekly (Apr 24th): Kioxia, SoftBank, Lasertec, Nintendo, Disco, Sumitomo Pharma

We analyzed JPX margin trading positions report for the past week and highlighted Kioxia (285A JP), SoftBank (9984 JP), Lasertec (6920 JP),...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Kyowa Kirin (4151 JP): 1Q26 Revenue Grow on EMEA & Out-Licensing, Guidance Partially Revised

​Kyowa Kirin sees strong revenue growth in 1Q26, with improved margins and revised profit guidance for 2026. Company looks to new drugs for future...

Tina Banerjee

Names that Are Hated and Loved by the Street in Japan....

It has been a while since we updated the "Hated by the Street" screen. So we thought it would be good to see which names made the list. Usually we...

Custom Products Group

Names Potentially Well Positioned to Beat Year-End Estimates

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half....

Custom Products Group

Names with Too Much "Other" On the Balance Sheet....

As I have mentioned before, a long time ago I worked at Panasonic in their IR department. One day when I was bored, I went to the Accounting...

Custom Products Group

JPX Margin Trading Weekly (Apr 24th): Kioxia, SoftBank, Lasertec, Nintendo, Disco, Sumitomo Pharma

We analyzed JPX margin trading positions report for the past week and highlighted Kioxia (285A JP), SoftBank (9984 JP), Lasertec (6920 JP),...

Ke Yan, CFA, FRM

Kyowa Kirin sees strong revenue growth in 1Q26, with improved margins and revised profit guidance for 2026. Company looks to new drugs for future...